Gina Vaccaro is an Oncology physician affiliated with Tennessee Oncology. OpenAlex indexes 81 publications with 7,011 citations (h-index 27); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
315 N Washington Ave Ste 230
Cookeville, TN 385012660
Telephone
931-400-0995Provider last certified this registry record 10 Jul 2025.
Clinical trials
- Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Sponsor: OHSU Knight Cancer Institute
Overall officialPhase 2CompletedNCT02427841
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
62 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year202559 payments$38,891openpaymentsdata.cms.gov ↗
- Astellas Pharma US IncProgram year202525 payments$26,602openpaymentsdata.cms.gov ↗
- Partner Therapeutics, Inc.Program year202514 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
59.2%Platinum-based Drug39.7%Oxaliplatin97%Carboplatin3%Part B, office-administered≥20 patientsMicrotubule Inhibitor18%Paclitaxel100%Part B, office-administered≥13 patients+ 2 more classes in this area
Metabolism & gastrointestinal
20.2%Other antiemetics18.6%Fosaprepitant100%Part B, office-administered≥18 patientsSerotonin-3 Receptor Antagonist1.6%Palonosetron hcl92%Ondansetron Odt8%Part D + Part B≥46 patients+ 2 more classes in this area
Sensory organs
8.2%Corticosteroid8.2%Dexamethasone sodium phosphate99%Dexamethasone1%Part D + Part B≥69 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Results from a phase 2 study of triplet blockade of the IL-27, PD-(L)1, and VEGF pathways with casdozokitug (casdozo, CHS-388) in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC).
Journal of Clinical Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Ian Flinn, MD
Tennessee Oncology
Kent Shih, MD
Tennessee Oncology
Wade Iams, MD
Tennessee Oncology
Lester Porter, MD
Tennessee Oncology
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”